Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
- 1 January 2013
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 73 (1) , 95-103
Abstract
Objective: To identify early predictors of long‐term outcomes in patients with relapsing–remitting multiple sclerosis (RRMS) treated with intramuscular (IM) interferon beta‐1a (IFNβ‐1a).Methods: A multicenter, observational, 15‐year follow‐up study of patients who completed ≥2 years in the pivotal trial of IM IFNβ‐1a for RRMS was conducted. One hundred thirty‐six patients participated in the 15‐year follow‐up (69 originally randomized to IM IFNβ‐1a and 67 to placebo). After the 2‐year clinical trial, treatment was not regulated by study protocol. Disease activity during the 2‐year trial was defined as: ≥2 gadolinium‐enhancing lesions (cumulative) on year 1 and/or year 2 magnetic resonance imaging (MRI); ≥3 new T2 lesions on year 2 MRI compared to baseline; and ≥2 relapses over 2 years. Odds ratios were calculated for early disease activity predicting severe Expanded Disability Status Scale (EDSS) worsening (worst quartile of change, ≥4.5 EDSS points) during the 15‐year interval.Results: The proportion of patients experiencing early disease activity was lower in patients on IM IFNβ‐1a than placebo for all disease activity markers (range, 23.5–29.0% vs 41.0–45.5%). In the IM IFNβ‐1a group, persistent disease activity predicted severe EDSS worsening: gadolinium‐enhancing lesions (odds ratio [OR], 8.96; p < 0.001); relapses (OR, 4.44; p = 0.010); and new T2 lesions (OR, 2.90; p = 0.080). In placebo patients, early disease activity was not as strongly associated with long‐term outcomes (OR range, 1.53–2.62; p = 0.069–0.408).Interpretation: Disease activity despite treatment with IFNβ is associated with unfavorable long‐term outcomes. Particular attention should be paid to gadolinium‐enhancing lesions on IFNβ therapy, as their presence strongly correlates with severe disability 15 years later. The results provide rationale for monitoring IFNβ‐treated patients with MRI, and for changing therapy in patients with active disease. ANN NEUROL 2013.Keywords
This publication has 18 references indexed in Scilit:
- Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple SclerosisPLOS ONE, 2011
- Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up studyMultiple Sclerosis Journal, 2010
- Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosisThe Lancet Neurology, 2009
- The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosisJournal of Neurology, 2005
- Defining interferon β response status in multiple sclerosis patientsAnnals of Neurology, 2004
- Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysisThe Lancet, 1999
- Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measureNeurology, 1997
- Self-Assessment of Neurologic Impairment in Multiple SclerosisNeurorehabilitation and Neural Repair, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992